Almirall has returned ulcerative colitis therapy Kappaproct to its originator company InDex Pharmaceuticals.
Almirall licensed exclusive rights to Kappaproct for the European market in March last year, but has now returned the drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?